Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Citius Pharmaceuticals, Inc. (CTXR : NSDQ)

• Company Description    Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care and prescription products. Citius Pharmaceuticals, Inc. is headquartered in Cranford, New Jersey. Number of Employees: 23

• Price / Volume Information    Yesterday's Closing Price: $0.70 Daily Weekly Monthly 20 Day Moving Average: 1,139,226 shares Shares Outstanding: 27.45 (millions) Market Capitalization: $19.25 (millions) Beta: 1.05 52 Week High: $2.48 52 Week Low: $0.48 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -24.85% -28.53% 12 Week -7.04% -14.06% Year To Date -9.77% -20.35%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11 Commerce Drive First Floor - Cranford,NJ 07016 USA ph: 908-967-6677 fax: - ir@citiuspharma.com http://www.citiuspharma.com

• General Corporate Information    Officers Leonard Mazur - Chief Executive Officer and Director Myron Holubiak - Executive Vice Chairman and Director Jaime Bartushak - Chief Financial Officer Suren Dutia - Director Eugene Holuka - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 17322U306 SIC: 2834 Fiscal Year Fiscal Year End: September Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 27.45 Most Recent Split Date: 11.00 (0.04:1) Beta: 1.05 Market Capitalization: $19.25 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.36 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.87 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.28 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 25.20% vs. Previous Quarter: -150.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -57.73% ROE 03/31/26 - -61.09 12/31/25 - -49.34 09/30/25 - -55.93 ROA 03/31/26 - -35.36 12/31/25 - -28.64 09/30/25 - -31.00 Current Ratio 03/31/26 - 0.58 12/31/25 - 0.99 09/30/25 - 0.62 Quick Ratio 03/31/26 - - 12/31/25 - 0.40 09/30/25 - 0.13 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - -978.26 12/31/25 - -958.32 09/30/25 - - Book Value 03/31/26 - 2.52 12/31/25 - 4.50 09/30/25 - 4.29 Inventory Turnover 03/31/26 - 0.05 12/31/25 - 0.04 09/30/25 - 0.00 Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©